PBYI Stock Analysis: Puma Biotechnology Looks Cheap, but the Pipeline Still Has to Matter This PBYI stock analysis starts with the obvious part: Puma Biotechnology looks cheap on a screen. The company is profitable, it trades around 12x trailing earnings, it finished 2025 with $97.5 million in cash and marketable securities, and management is guiding …
Hudson Technologies is one of those small-cap stocks that sounds boring until you read the numbers and the regulations. That is why this HDSN stock analysis matters right now. Hudson sells and reclaims refrigerants, a niche business that benefits when the supply of virgin HFC refrigerants gets tighter under the AIM Act. At roughly a …
Alignment Healthcare reports Q1 2026 earnings after the bell today, April 30. The stock sits at $21.72 — roughly flat for the year. But the business has never grown this fast. Here are the numbers heading into tonight’s report, and where the actual risk lives. ## FY2025: The Growth Was Real $3.95 billion in revenue …
MTA at $6.62: Gold Royalty Without the Mining Risk Gold hit $4,700 an ounce this week. If you own a gold miner, you’re celebrating. You’re also exposed to diesel costs, labor disputes, equipment failures, and the fact that mining is genuinely hard. Metalla Royalty & Streaming (NYSE American: MTA) offers a cleaner trade. The company …
Evolv Technologies (NASDAQ: EVLV) just closed its first profitable year on an adjusted EBITDA basis, grew revenue 40%, and raised 2026 guidance. The stock sits at $6.65 with four analysts pegging the target at $9.12-$10.00. That’s 37-50% upside from here. The question isn’t whether the business is working — it clearly is. The question is …
The Quick Version Energy Vault (NYSE: NRGV) just reported FY2025 revenue of $203.7 million — up 340% year-over-year — with Q4 revenue alone hitting $153.3 million. The company turned adjusted EBITDA positive in Q4 for the first time, gross margin expanded to 23.6%, and contracted backlog exploded to $1.3 billion (up 300% from the prior …
This CDNA stock analysis gets interesting fast: CareDx is a transplant diagnostics company that just put up $380 million in 2025 revenue, up 14% year over year, guided to $420 million to $444 million for 2026, and still trades at roughly 2.7 times sales. For a company with category leadership, real profitability, and an earnings …
Small-cap promotion trap checklist is the phrase I wish more retail investors searched before they chased the latest “hidden gem” in a Telegram room. In 2026, the scam is not always a pink-sheet boiler room anymore. Sometimes it looks like a slick Substack thread, a Discord callout, or a social feed full of screenshots that …
Serve Robotics at a Glance Serve Robotics (NASDAQ: SERV) builds sidewalk delivery robots. Spun off from Uber in 2021, the company now operates 2,000 robots across 20 cities and 6 metro areas. Revenue is tiny — $2.7 million in all of 2025. But the 2026 revenue guide just jumped to $26 million. That’s a 10x …
AbCellera looks cheap for a reason, but the setup is finally getting interesting. ABCL stock analysis in April 2026 comes down to three facts: revenue snapped back to $75.1 million in 2025, the company still has roughly $700 million of available liquidity, and lead menopause program ABCL635 has a real catalyst window with Phase 1 …